Share Price:

APNASPENAspen Pharmacare Hldgs228590 (0.00%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Day: April 4, 2007

Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Co Cork, Ireland (April 4th, 2007) – Tibotec Pharmaceuticals Ltd. has signed a royalty-free, non-exclusive license agreement with Aspen of South Africa. Aspen will register, package and distribute the protease inhibitor PREZISTA™ (darunavir, DRV) in sub-Saharan Africa. Tibotec has selected Aspen because of the company’s extensive African distribution network and pioneering endeavors in enhancing access… Continue reading Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.